Prospective cohort study links pre-diagnostic clonal hematopoiesis to higher overall death rates in cancer patients, indicating its prognostic significance.
Key Points
Cancer patients with pre-diagnostic clonal hematopoiesis exhibited a higher overall death rate (HR 1.18).
During follow-up, 1162 deaths occurred in the CHIP group compared to 17,825 in the reference group.
Higher rates of cancer-specific death were noted for myeloproliferative neoplasms and multiple myeloma.
Findings suggest that pre-diagnostic CHIP may influence prognostic assessment in cancer care.